key: cord-1001581-4sq7t6hg
authors: Dufloo, Jérémy; Grzelak, Ludivine; Staropoli, Isabelle; Madec, Yoann; Tondeur, Laura; Anna, François; Pelleau, Stéphane; Wiedemann, Aurélie; Planchais, Cyril; Buchrieser, Julian; Robinot, Rémy; Ungeheuer, Marie-Noelle; Mouquet, Hugo; Charneau, Pierre; White, Michael; Lévy, Yves; Hoen, Bruno; Fontanet, Arnaud; Schwartz, Olivier; Bruel, Timothée
title: Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies.
date: 2021-04-20
journal: Cell Rep Med
DOI: 10.1016/j.xcrm.2021.100275
sha: 14fb2de2efdae385c49b30b19d4a1ef078e07a00
doc_id: 1001581
cord_uid: 4sq7t6hg

A large proportion of SARS-CoV-2 infected individuals remains asymptomatic. Little is known about the extent and quality of their antiviral humoral response. Here, we analyze antibody functions in 52 asymptomatic infected individuals, 119 mild and 21 hospitalized COVID-19 patients. We measured anti-Spike IgG, IgA and IgM levels with the S-Flow assay and map IgG-targeted epitopes by Luminex. We also evaluated neutralization, complement deposition and Antibody-Dependent Cellular Cytotoxicity (ADCC) using replication-competent SARS-CoV-2 or reporter cell systems. We show that COVID-19 sera mediate complement deposition and kill infected cells by ADCC. Sera from asymptomatic individuals neutralize the virus, activate ADCC and trigger complement deposition. Antibody levels and functions are lower in asymptomatic individuals than in symptomatic cases. Antibody functions are correlated, regardless of disease severity. Longitudinal samplings show that antibody functions follow similar kinetics of induction and contraction. Overall, asymptomatic SARS-CoV-2 infection elicits polyfunctional antibodies neutralizing the virus and targeting infected cells.

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) emerged in 2019 and became pandemic in 2020 1, 2 . SARS-CoV-2 is responsible for the Coronavirus disease 2019 (COVID-19) 3 . As of March 27, 2021 , almost 125 million individuals were infected and 2.7 million have died of COVID-19. The rapid spread of the virus has overwhelmed healthcare organization in many areas. In the absence of prophylactic or therapeutic strategies, governments used non-pharmaceutical measures to decrease viral transmission 4 . As restrictive policies were relaxed, many countries experienced new epidemic waves, demonstrating the necessity for population immunity, triggered either by infection or vaccination, to limit SARS-CoV-2 circulation. Therefore, the immune response induced by SARS-CoV-2 is under intense investigation, aiming at informing vaccine design, identifying correlates of protection and determining the duration of protective immunity.

The outcome of SARS-CoV-2 infection is highly variable, ranging from asymptomatic disease to life-threatening acute respiratory distress syndrome 5, 6 . About half of infected individuals remain asymptomatic 7, 8 . Males, the elderly, and people suffering from diabetes, obesity and cardiovascular diseases have an increased risk of admission to intensive care unit (ICU) and death 6, 9 . Severe COVID-19 is due to immunological dysfunctions, including impaired type I interferon response [10] [11] [12] [13] increased inflammation [14] [15] [16] , complement activation 17 and endothelial stress 18 . Because of this overactivation of the immune system and prolonged antigenic exposure, survivors of severe COVID-19 display a strong immune memory to the virus, as determined by antibody titers and CD4 + T cell restimulation 19, 20 . Mild and asymptomatic infections induce seroconversion and production of neutralizing antibody 21, 22 , but titers are lower in asymptomatic individuals 22 . Whether such responses are protective is unknown. A deeper understanding of the immune response after asymptomatic SARS-CoV-2 infection is needed.

The Spike protein of SARS-CoV-2 is responsible for viral entry by interacting with the angiotensinconverting enzyme 2 (ACE2) receptor 23 . It is a class I fusion protein, which requires proteolytic cleavage for activation. The two subunits S1 and S2 assemble into a trimer of heterodimers to form the mature Spike 24 . The S1 subunit samples "closed" and "open" conformations, the latter exposing the receptor binding domain (RBD), the main target of neutralizing antibodies [25] [26] [27] [28] . The Spike protein is exposed at the surface of viral particles and infected cells 29 , making them sensitive to antibody targeting. Antiviral activities of antibodies are not restricted to neutralization of viral particles. Infected cells covered by antibodies can be eliminated through various mechanisms, including antibodydependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) [30] [31] [32] [33] [34] . Those activities rely on the fragment crystallizable (Fc) domain of antibodies and cognate Fc Receptors (FcR) 35 . Fc-effector functions are necessary for optimal efficacy of antibodies in both therapeutic and prophylactic settings [36] [37] [38] . The capacity of antibodies to elicit Fc-effector functions is governed by antibody specificity, isotypes and glycosylation 39 . Thus, Fc-mediated antiviral activities cannot be predicted from binding and neutralization data and require functional evaluation. Fc-effector functions in SARS-CoV-2 infection remain understudied. Antibodies in sera from critical COVID-19 patients form immune complexes that can trigger NK cell activation and complement deposition 40 . Induction of afucosylated IgG anti-Spike antibodies with increased Fc binding capacity correlates with severity of COVID-19 41 . However, whether polyfunctional antibodies are induced during asymptomatic COVID-19 disease and whether they can eliminate infected cells remain unknown.

Here, we established cellular assays to evaluate ADCC and complement activities of sera from COVID-19 patients with different disease severities. We combined these assays with measurements of antibody titers and neutralization. Altogether, our results indicate that SARS-CoV-2 asymptomatic infection induces a polyfunctional antibody response.

We first determined whether antibodies from COVID-19 patients may activate the complement after binding to SARS-CoV-2-infected cells. We used as target cells the lung epithelial cell line A549 expressing ACE2 (A549-ACE2 cells) 29 . Cells were infected with SARS-CoV-2 at a multiplicity of infection (MOI) of 1. After 24h, cells were incubated with heat-inactivated (HI) serum from either prepandemic or COVID-19 individuals as a source of antibodies (dilution 1:100). We selected a panel of 11 sera from symptomatic (n=9) or asymptomatic (n=2) SARS-CoV-2-infected individuals identified in two previous sero-epidemiological studies 42, 43 (Table S2) . Sera sampled before 2019 (pre-pandemic samples) were used as controls (n=12). The source of complement was normal human serum (NHS) (dilution 1:2). Heat-inactivated human serum (HIHS) was used as control ( Figure 1A) . After 4h of incubation, cells were stained with anti-C3b/iC3b and anti-Spike antibodies to examine complement deposition and SARS-CoV-2 infection, respectively. C3b/iC3b deposition (later referred to as C3 deposition) was measured in Spike+ cells. As shown in one representative experiment ( Figure 1B) , we did not observe C3 deposition in the absence of antibodies nor with a pre-pandemic serum. In contrast, with a COVID-19 serum, C3 deposition occurred on 79% of infected cells ( Figure 1B) . To calculate a cutoff of positivity, we determined the mean signal of the 12 pre-pandemic sera and added 3 standard deviations (S.D.) ( Figure 1C and S1A). All but one COVID-19 serum displayed C3b deposition above this cutoff (p<0.0001; Mann-Whitney test) ( Figure 1C and S1A). No C3 deposition was observed with HIHS ( Figure 1B and S1B). Despite C3 deposition, we did not observe killing (complement-dependent cytotoxicity, CDC) of infected cells ( Figure 1D and S1C). We then performed a dose-response analysis of the 3 COVID-19 individuals with the highest activity ( Figure S1D ). It reveals an efficient complement activation at high serum dilution (ED50 up to 1151) and complete lack of activity in pre-pandemic samples (ED50<100). We also used U2OS-ACE2-GFPsplit cells (also termed S-Fuse cells) 29 . This reporter cell line allows quantification and live imaging of SARS-CoV-2 replication by measuring the formation of GFP+ syncytia upon infection. Similarly, we detected complement deposition, but no CDC of S-Fuse infected cells (not shown).

To evaluate the contribution of anti-Spike antibodies on complement deposition, we engineered Raji cells expressing the Spike protein. We chose Raji cells because they lack CD59, a potent CDC inhibitor 30 . Raji-Spike cells were incubated with HI serum from either pre-pandemic or convalescent COVID-19 individuals (dilution 1:33), and normal human serum (NHS) as a source of complement (dilution 1:2). After 24h, cell death was assessed using a viability dye ( Figure 1E ). COVID-19 sera displayed CDC activity above the threshold determined with the pre-pandemic sera (p<0.0001; Mann-Whitney test) ( Figure 1F ). The CDC activity on Raji-Spike cells positively correlated with C3 deposition on A549-ACE2 infected cells (r=0.91, p<0.0001, Spearman correlation) ( Figure 1G ).

We then assessed the ADCC activity of sera from COVID-19 patients. To visualize ADCC, we used SARS-CoV-2 infected S-Fuse cells as targets 29 . S-Fuse cells were infected for 18h with SARS-CoV-2 at a MOI of 0.1 and incubated with heterologous primary NK cells (ratio 1:1) in the presence or absence of serum (dilution 1:100). After 4h of co-culture, the area of infected (GFP+) cells was quantified using an automated microscope (Figure 2A) . GFP+ syncytia formed after infection were readily visible ( Figure 2B ). Adding NK cells (ratio 1:1) decreased the GFP area, to a similar extent in the "no serum" and "pre-pandemic serum" conditions, likely due to basal cytotoxic activity of NK cells against infected cells independently of any antibody ( Figure 2B ). The GFP signal almost completely disappeared in the presence of a convalescent COVID-19 serum ( Figure 2B) , demonstrating an induction of ADCC by NK cells. Of note, A549-ACE2 infected cells were not sensitive to ADCC (not shown). We thus used S-Fuse cells to interrogate our panel of COVID-19 sera (n=11; 9 symptomatic and 2 asymptomatic individuals) and pre-pandemic samples (n=13) using six donors of NK cells ( Figure 2C) . We calculated the extent of GFP elimination triggered by each serum in comparison to the condition with NK cells and no serum. The 6 NK donors were active in this test, with variations in their efficacy ( Figure S2A ). The mean value of pre-epidemic samples was used to determine a threshold of positivity (mean + 3 S.D). Using this method, 10 out of the 11 tested COVID-19 sera displayed ADCC activity (p<0.0001; Mann-Whitney test) ( Figure 2C ). Titration of the 3 COVID-19 individuals with the highest activity shows efficient ADCC activity at high serum dilution (ED50 up to 6330) and a lack of activity in pre-pandemic samples (ED50<100) ( Figure S2B) . Importantly, sera J o u r n a l P r e -p r o o f 4 from either COVID-19 patients (n=10) of pre-pandemic individuals (n=15) cells did not display any killing activity in the absence of NK cells ( Figure S2C ). Variations in the ratio of NK cells to target cells impacted the spontaneous killing of NK cells. We did not detect an elimination of infected cells at a 1:3 (NK to Target) ratio and only a slight spontaneous killing at a 1:1 ratio ( Figure S2D ). Serum-specific ADCC activity was maximal at a 1:1 ratio and started to decrease at a 1:10 NK cells:target cells ratio ( Figure S2E) .

We then performed video-microscopy experiments to determine whether the decrease in GFP was due to a killing of infected cells. SARS-CoV-2-infected S-Fuse cells were cultivated with NK cells and COVID-19 or pre-pandemic sera. Propidium iodide (PI) was added to the culture medium to monitor cell death. The infected GFP+ cells were tracked, and their viability was determined ( Figure 2D ). After 4h of co-culture, 100% of infected cells were killed when NK cells and COVID-19 serum were present ( Figure 2D ). NK cells alone or with a pre-pandemic serum reduced S-Fuse viability to a lower extent (p<0.0001; log-rang Mantel-Cox test) ( Figure 2D) . Analysis of the movies revealed that NK cells established contacts with infected cells prior to death ( Figure 2E and Movie S1). These results show that sera from COVID-19 patients kill SARS-CoV-2-infected cell by ADCC.

We also used Raji-Spike cells and Jurkat-CD16-NFAT-rLuc reporter cells as a simple assay to evaluate ADCC of COVID-19 sera. This system measures the capacity of a serum to activate NFAT through CD16 (the pathway initiating ADCC in NK cells) in the presence of antigen-expressing target cells ( Figure 2F ). The convalescent sera activated CD16 above the threshold calculated with the prepandemic samples (p<0.0001; Mann-Whitney test) ( Figure 2G ). The extent of CD16 activation correlated to ADCC activity against S-Fuse infected cells, suggesting that anti-Spike antibodies contribute to the killing of infected cells (r=0.77, p<0.0001; Spearman correlation) ( Figure 2H ).

Overall, these data show that sera from SARS-CoV-2 infected individuals harbor polyfunctional antibodies triggering complement deposition and ADCC. NK cells eliminate infected cells in the presence of specific antibodies, whereas complement activation is non-lytic, at least in the cell lines tested here.

We then took advantage of two sero-epidemiological studies conducted in a high school and in primary schools, respectively 42, 43 , to determine whether sera of COVID-19 asymptomatic and symptomatic individuals differ in their ability to trigger ADCC and complement deposition. In the first cohort, we identified a group of 21 seropositive individuals, who did not report any symptoms (asymptomatic individuals; AS) ( Table S2) . As a control, we randomly selected seropositive individuals who reported at least one symptom (symptomatic individuals, S; n=76 among 137). These individuals suffered from a mild disease, as none required external oxygen supplementation nor hospitalization. The symptomatic group reported their first symptoms on average 45 days prior to blood sampling. AS were younger than S individuals (16 vs 30 years old; Table S2 ).

With the sera from these 97 individuals, we first measured the presence of antibodies binding the Spike, at a 1:300 dilution ( Figure 3A) . We adapted our S-Flow assay, which allows sensitive and quantitative assessment of anti-Spike IgG by flow cytometry 19 , to measure IgA and IgM ( Figure 3A) . Consistently with our prior identification as being seropositive, AS and S individuals harbored IgG antibodies, as determined by a percentage of Spike+ cells above the cutoff of 20% ( Figure 3A) . The frequency of IgA+ and IgM+ cells tended to be lower in AS individuals with no significant differences ( Figure 3A) . We did not observe differences by analyzing the intensity of binding for individuals positive for IgG, IgA and IgM ( Figure S3A ). We then measured IgG binding titers by serial dilutions. Titration curves of AS were below S individuals ( Figure 3B ). Effective dilution 50% titers (ED50) were significantly lower in AS (p=0.018; Mann-Whitney test) ( Figure 3B ). As the Spike protein contains multiple epitopes 27 , we used Luminex to map anti-S1, anti-S2, anti-RBD and anti-Spike IgGs ( Figure  3C ). We also included the N protein ( Figure 3C ), as well as antigens from hCoV-229E and hCoV-NL63, and from Adenovirus 40, Influenza A, Mumps and Rubella viruses, to assess pre-existing immunity to human seasonal coronaviruses and other viruses ( Figure S3B-D) . The overall response to S1, S2, RBD, Spike and N antigens tended to be lower in AS than in S albeit not significant ( Figure  3C and Figure S3B ). We did not observe differences between AS and S in the IgG response to hCoV-229E and NL63 ( Figure S3C ). The response to the antigens from the other viruses was similar between the two groups, except for Influenza A, likely reflecting the age difference (p=0.001; Mann-5 Whitney test) ( Figure S3D-E) . Altogether, these data show that the intensity of the antibody response specific to SARS-CoV-2 is slightly lower in asymptomatic than in mildly symptomatic individuals.

To further document the function of anti-SARS-CoV-2 antibodies, we measured the capacity of sera to neutralize lentiviral Spike pseudotypes in 293T-ACE2 cells (pseudo-neutralization) 19 and SARS-CoV-2 virus in S-Fuse cells (neutralization) 29 . We also quantified complement deposition and ADCC activities using the two Raji-Spike-based assays. Sera were interrogated with serial dilutions to calculate exact titers for these four functions. Most of the sera from AS and S individuals were active in these assays (Figure 4) . Sera from AS display titers slightly below those from S ( Figure 4A ). The differences in ID50 were however not significant ( Figure 4B ). We also compared the maximal level of the response ( Figure 4C ). The level of antibody-mediated complement activation was significantly higher in S than in AS (p=0.036; Mann-Whitney test) ( Figure 4C ).

Altogether, our data show that sera of SARS-CoV-2-infected individuals harbor polyfunctional antibodies. Asymptomatic individuals have a decreased capacity to activate the complement and lower IgG titers.

We then sought to perform an unsupervised analysis of antibody features measured in symptomatic and asymptomatic individuals. We first created correlation matrices of antibody characteristics in each group ( Figure 5A ). The response to antigens from other viruses and hCoV did not correlate to SARS-CoV-2-related antibody properties. The features corresponding to SARS-CoV-2 appeared positively correlated in both groups. Anti-influenza A IgG measured by Luminex negatively correlated with some SARS-CoV-2 features in AS, but correlation coefficients remained low. ADCC ED50 and maximum activity more strongly correlated to other features in AS compared to S. The IgMassociated features (IgM MFI and IgM %) appeared more strongly correlated to other features in the S group ( Figure 5A ). Altogether, this analysis reveals slight differences in ADCC and IgM responses between AS and S groups, with an overall high level of coordination in each group. Consistently, Principal Component Analysis (PCA) failed to separate individuals according to their symptoms, showing that no combination of antibody features allowed a strict segregation of the two groups ( Figure 5B ). This observation was confirmed by unsupervised hierarchical clustering ( Figure S4 ).

Overall, this unsupervised analysis shows that the antibody response to SARS-CoV-2 is coordinated in AS and S groups, with differences in ADCC and IgM responses.

To further characterize the functionality of antibodies in COVID-19 patients, we analyzed a second cohort established in primary schools of Crépy-en-Valois (n=1340; Fontanet et al. 43 and Table S3 ). We chose to analyze separately this second group of AS to ensure that the symptomatic individuals used in the comparisons were infected during the same epidemic wave, in order to compensate for the lack of date of infection for asymptomatic individuals. This cohort included a large proportion of children (6-11 years old). We selected all asymptomatic individuals (AS; n=31) and formed a group of gender-and age-matched mildly symptomatic individuals (S; n=43 among the 107 of the cohort) ( Figure S5A ). We also included COVID-19 hospitalized individuals from the FrenchCOVID cohort (H; n=21). As expected, when compared to AS and S, hospitalized patients were older, more often male and sampled sooner after onset of symptoms (Table S4 and Figure S5B ).

We assessed the anti-Spike antibody profile by S-Flow in the 95 individuals forming these three groups (AS, S and H) ( Figure 6A ). Frequencies of IgG, IgA and IgM were significantly higher in hospitalized patients than in AS (p=0.0101, p<0.0001 and p<0.0001, Kruskal-Wallis test). When compared to S individuals, hospitalized patients harbored significantly more IgA and IgM (p=0.0002 and p<0.0001, Kruskal-Wallis test). ( Figure 6A ). Measuring the MFI of binding of IgG-, IgA-and IgMpositive individuals showed higher IgG response in hospitalized patients compared to AS and higher IgA response compared to S ( Figure S6A) . We also performed a restricted analysis to compare only AS and S individuals. The frequency of IgA and IgM positive cells, and the MFI of IgG positive cells were significantly higher in S individuals (p=0.0007, p=0.014, p=0.018, respectively; Mann-Whitney test) ( Figure S6B ). J o u r n a l P r e -p r o o f 6 We then measured pseudo-neutralization, ADCC and complement deposition capacity of the 95 sera. Antibody functions paralleled that of antibody binding, with the highest and lowest activities in hospitalized and asymptomatic individuals, respectively ( Figure 6B ). Mildly symptomatic individuals scored between hospitalized and asymptomatic individuals ( Figure 6B ). S resembled AS patients for the level of ADCC, with a lower activity than hospitalized patients (p<0.0001, Kruskal-Wallis test), but were similar to hospitalized individuals for complement deposition ( Figure 6B) . Interestingly, neutralization, CDC, ADCC and anti-S IgG were significantly higher in hospitalized individuals who survived when compared to fatal COVID-19 cases ( Figure S6C ).

To further characterize the anti-Spike response across these 3 groups, we performed unsupervised PCA analysis including the nine antibody features. AS and S clustered together as previously observed in the first groups. In contrast, H individuals appeared divergent, with most individuals clustering apart on the first component (PC-1) ( Figure 6C ). The contributions of the 9 features to PC-1 ranged from 8% to 14%, indicating that H individuals had an overall higher response, rather than an increase in a limited set of features ( Figure S6D ).

We then mixed the different groups of individuals that we separately analyzed, in order to increase the power of our statistical tests. We thus compared the antibody response of all AS and S individuals (n=52 and n=119, respectively) ( Figure S7A-C) . Frequencies of IgG, IgA and IgM were significantly lower in AS than in S. Moreover, the MFI of IgG binding, as well as neutralization and complement activities, were significantly lower in AS than in S. ADCC activity was also lower but did not reach significance. Correlation between age and antibody levels revealed a positive association for IgG, IgA and IgM in symptomatic individuals ( Figure S7D ).

The results that asymptomatic individuals harbor a polyfunctional anti-Spike antibody response which is lower than is symptomatic individuals were thus confirmed in a second group of infected persons. Our results also show that our group of hospitalized individuals, who were sampled earlier, are older and more often male, displays the highest levels of antibodies and functions.

We then aimed at determining the dynamics of antibody functions after SARS-CoV-2 infection. We identified 7 hospitalized patients and 22 mildly symptomatic COVID-19 cases with longitudinal sampling in our cohorts. As only symptomatic individuals were invited for a second sampling in our sero-epidemiological studies, no longitudinal samples were available for asymptomatic individuals. Hospitalized patients had the highest temporal resolution and were sampled early after onset of symptoms, with up to 8 samples per individual, from day 6 to 21 post-symptoms onset ( Figure S5B ). We thus documented the induction of the polyfunctional response in these hospitalized patients ( Figure 7A ). Mildly symptomatic individuals were sampled twice, with a 25-29 days interval. The first sampling was usually performed 21 after onset of symptoms. The mildly symptomatic individuals allowed us to assess the contraction of the immune responses ( Figure 7B ). We measured IgG, IgA and IgM levels, ADCC, complement deposition, and neutralization or pseudo-neutralization, in the longitudinal samples available.

In hospitalized patients, all functions, except complement deposition, were induced simultaneously between 6 and 21 days after onset of symptoms ( Figure 7A ). This delay may reflect a lower sensitivity of the assay, a slower appearance of complement-potent antibodies, or a requirement of high antibody titers to trigger this activity.

In mildly symptomatic individuals, we observed a significant decrease in antibody binding titers and their neutralization and ADCC function over time (p=0.011, p=0.001, p=0.001, respectively; Wilcoxon test) ( Figure 7B) . A decline of complement deposition activity was also visible over time but this was not significant.

7

In this study, we show that asymptomatic individuals mount a polyfunctional anti-SARS-CoV-2 humoral response. Our results confirm and extend reports of decreased antibody titers in asymptomatic individuals 22, 44 , in which Fc-associated antibody functions were not analyzed. The levels of antibodies are lower in asymptomatic individuals, and therefore their neutralizing activity and Fcmediated functions are also reduced. The differences are however modest and not always significant. Our results were consistent across two cohorts, despite minor differences such as lower IgA and IgM levels in asymptomatic individuals in the second cohort, when compared to the first one. These differences might be attributed to various sampling times after onset of symptoms and to age variations. Indeed, the two serological investigations were not conducted at the same time, explaining the difference in the average time post-symptoms onset. This is the reason why we chose to keep the analysis separated, to avoid comparing AS to S infected a different epidemic wave. However, combining AS and S individuals from the two cohorts provided comparable results, albeit differences were more significant, probably because of increased statistical power.

We also observed that hospitalized individuals display high levels of anti-SARS-CoV-2 specific antibodies. However, our group of hospitalized individuals were sampled earlier, are older and more often male than our groups of symptomatic and asymptomatic individuals. Interestingly, it has been reported that antibody binding and neutralization are higher in severe and critical cases 19, 20, 28, 45 . This suggests that disease severity drives the increase in antibody levels and functionality, as reported by others 46, 47 . The future investigation of antibody functions in age-and gender-matched groups will uncover the contribution of these parameters to the immune response to SARS-CoV-2. We further show that complement deposition and ADCC activities are also elevated in hospitalized patients. An increase in soluble C5a levels proportional to COVID-19 severity and high levels of C5aR1 expression in blood and pulmonary myeloid cells have been reported 17 . The origin of the activation of the C5a-C5aR1 axis in severe COVID-19 remains unknown 48 . Whether antibody-mediated complement activation at the surface of infected cells participates to disease severity will deserve further investigation.

It is noteworthy that the neutralizing activity of antibodies correlates with their ability to mediate complement deposition and ADCC, irrespectively of the severity of the disease. A pilot longitudinal analysis performed in some of the hospitalized patients further demonstrated that the acquisition of the different functions similarly increased overtime. The ability to trigger complement deposition was however delayed by one week, compared to ADCC and neutralization. This may be due to a lower sensitivity of our complement test, or to the fact that complement deposition requires higher antibody titers than the other functions. By analyzing mildly symptomatic patients at two time points, sampled up to 70 days post symptom onset, we also observed a decline of antibody levels and function. A recent pre-print suggests that neutralization decay more rapidly than ADCC 49 . This suggests that neutralization and Fc-mediated activities are not performed by the same antibodies, and/or that the half-lives of neutralizing and non-neutralizing antibodies are different. Consistently, it has been shown that anti-spike IgG, IgA and IgM follow distinct kinetics of induction and contraction 50 . An analysis of monoclonal antibodies derived from convalescent patients will help determining whether the different functions can be dissociated and may depend on the isotype or the epitope recognized by individual antibodies.

What are the consequences of complement deposition at the plasma membrane? We show here that sera from COVID-19 patients readily triggered C3 deposition at the surface of infected S-Fuse or A549-ACE2 cells, but C3 deposition did not induce detectable cell death. This may be due to the presence of molecules such as CD59, CD55 and CD46 that counteract complement dependent killing. Raji-Spike cells, which lack CD59 30 , were indeed readily killed after complement deposition. In contrast, infected S-Fuse cells were rapidly eliminated by NK cells, when anti-SARS-CoV-2 antibodies were added to the culture medium. Our results suggest that NK cells are more potent than complement to kill SARS-CoV-2-infected cells after activation by antibodies. This is in line with previous observations with other viruses. For instance, HIV-1-infected cells may be eliminated by NK cells but not by CDC [30] [31] [32] . In COVID-19 patients, the main cellular targets of SARS-CoV-2 are ciliated cells from the airways and type II alveolar pneumocytes 51 . The viral receptor ACE2 is expressed in other tissues than the respiratory tract, and several studies have demonstrated that SARS-CoV-2 has a large cellular tropism 52, 53 . Levels of molecules regulating CDC and ADCC vary among cell types 54, 55 . Thus, it is likely that these cells display different susceptibilities to ADCC and CDC. Future work will J o u r n a l P r e -p r o o f 8 help understanding the sensitivity of natural target cells to antiviral antibodies, the fate and role of infected cells coated with complement, and the overall contribution of non-neutralizing antibody functions to the immune response to SARS-CoV-2.

The levels of antibodies targeting other viruses, including two seasonal coronaviruses were similar in asymptomatic and symptomatic individuals, suggesting that these previous infections did not impact disease severity. One noticeable exception was a higher titer of anti-Flu antibodies in symptomatic persons. The reasons for this remain to be characterized, but a simple explanation may be related to the older age of symptomatic individuals in the first cohort.

Our data did not provide a scenario explaining why some individuals remain asymptomatic. Rather, it shows that the antibody response of AS individuals, despite being lower, is not dramatically different from that of S patients. It has been reported that neutralizing IgA dominate the early neutralizing antibody response to SARS-CoV-2 56 . Rapid IgA responses may be more prevalent in AS vs S subjects, highlighting a difference between these two categories of individuals 57 . Thus, an early induction of functional antibodies may contribute to the asymptomatic phenotype. A rapid control of the virus likely decreases the overall antigenic burden, also providing an explanation for the lower antibody response observed in asymptomatic individuals at later time points. Challenging this hypothesis would require longitudinal sampling of asymptomatic individuals. This was not possible in our study as AS were identified retrospectively, through sero-epidemiological studies. However, we observed a tendency for a higher correlation between the MFI of IgA and other antibody features in asymptomatic individuals, suggesting that they may harbor a distinctive IgA profile. Thus, a careful assessment of the kinetic of the immune response in AS individuals, and the relationship between the IgA response and other immune component may help understanding the mechanisms underlying asymptomatic control of SARS-CoV-2 infection.

Vaccines under development aim at producing neutralizing anti-Spike antibodies 58 . The Fc region is required for optimal efficacy of anti-Spike monoclonal antibodies in vivo through mechanisms that may involve those described here 59, 60 . Non-neutralizing antibodies participate to protection offered by experimental vaccines against influenza or HIV 61, 62 . It will be of interest to assess whether SARS-CoV-2 vaccine candidates elicit non-neutralizing antibody functions, and whether these functions correlate with vaccine efficacy.

In conclusion, we show here that asymptomatic individuals mount a humoral immune response only slightly decreased when compared to symptomatic SARS-CoV-2 infections. This response includes, in addition to neutralization, the ability to trigger ADCC and complement deposition. Our results warrant further analysis of neutralization and other antibody functions in the evaluation of vaccine candidates and the study of COVID-19 immunopathology.

Our study has limitations. The first one is the absence of information regarding the date of virus acquisition in AS individuals. However, both S and AS were sampled at the beginning of the epidemic in Northern France and were likely infected within a short time frame. This is also why we analyzed the two groups of AS separately, to compare them to S individuals infected during the same epidemic wave. Another limitation is the lack of PCR confirmation for AS and mildly symptomatic individuals. Our analysis is therefore restricted to individuals who have seroconverted. Moreover, the different groups were not all age-matched. In our first group, AS individuals were, as expected, younger than S individuals. This was balanced in our second group, in which we selected S individuals to match the age of the AS group, but hospitalized individuals were older than AS and S in this study. In addition, hospitalized individuals were more often male. These biases limit our interpretation of the link between ADCC and complement levels, and hospitalization. Future work will help shedding light on the influence of age and other clinical and biological characteristics on the intensity and polyfunctionality of the antibody response. of the CORSER studies. B. Complement deposition on infected cells was measured after culture with or without a control or a COVID-19 serum in presence of normal (NHS) or heat-inactivated (HIHS) human serum. One representative experiment is shown. Percentages indicate the proportion of C3+ cells among infected (Spike+) cells. C. Complement deposition with pre-pandemic (n=12) and COVID-19 patients' (n=11) sera. The percentage of C3+ cells among infected cells is represented. Each dot represents the mean of 3 independent experiments for one serum donor. D. Complement-dependent cytotoxicity (CDC) of infected cells was calculated as the relative disappearance of Spike+ cells in the NHS compared to HIHS condition, with pre-pandemic (n=12) and COVID-19 patients' (n=11) sera. Each dot represents the mean of 3 independent experiments. E. Schematic of the complement activation test on Raji-Spike cells. F. Raji-Spike cells were cultured with sera from pre-pandemic individuals (n=12) or COVID-19 patients (n=11) and serum from a healthy individual as a source of complement. Each dot represents a different serum. G. Correlation of the C3 deposition on A549-ACE2 infected cells and CDC of Raji-Spike cells induced by sera from pre-pandemic individuals (grey, n=12) and COVID-19 patients (blue or red, n=11). Correlation r and p-value were calculated using Spearman correlation test. The dotted line indicates the threshold calculated with pre-pandemic sera. Blue: asymptomatic individuals; Red: symptomatic patients. In C, D and F, the bar indicates the mean and a Mann-Whitney test was performed (ns. not significant, ****p<0.0001). See also Figure S1 and Tables S1-S2.

Representative images of the ADCC assay. Infected cells created GFP+ syncytia (green). Nuclei were stained with Hoechst (blue). Scale bar: 400µm. C. Quantification of the ADCC triggered by pre-pandemic (n=13) or COVID-19 (n=11) sera. Each dot represents the mean of 6 donors of NK cells for one serum donor. D. The survival of infected cells was followed by live imaging without NK cells (green, n=22) or with NK cells and no serum (black, n=18), a pre-pandemic serum (grey, n=18) or a COVID-19 serum (red, n=20). Results from two independent experiments are represented. Log-rank (Mantel-Cox) test (****p<0.0001). E. Time-lapse of the ADCC of an infected cell by a NK cell in the presence of a COVID-19 serum. GFP indicates infected cells. PI was added to monitor cell death in red. The NK cell that contacts the infected cell is indicated with arrowhead. Scale bar: 30µm. F. Schematic of the CD16 activation test. G. Raji-Spike cells were co-cultured with Jurkat-CD16-NFAT-rLuc in presence of pre-pandemic (n=13) or COVID-19 (n=11) sera for 18h. The ADCC score was measured as the fold increase of Luciferase expression over the "no serum" condition. H. Correlation of the ADCC and the NFAT test score ED50 with sera from pre-pandemic individuals (grey, n=13) and COVID-19 patients (blue or red, n=11). Correlation r and p-value were calculated using Spearman correlation test. Blue: asymptomatic individuals; Red: symptomatic patients. Dotted line: positivity threshold calculated with pre-pandemic sera. In C and G, the bar indicates the mean and a Mann-Whitney test was performed (****p<0.0001). See also Figure S2 and Tables S1-S2. C. Luminex analysis of the antibody response against receptor binding domain (RBD), S1 and S2 subdomains of the Spike, full Spike and nucleoprotein (NP) for AS (blue line; n=21) and S (red line; n=76) sera. The median of MFI for AS and S sera are represented. In A and C, a Mann-Whitney test was performed (*p<0.05) and the bar indicates the median. See also Figure S3 and Table S2 . For each assay, the ED50 is represented against the day post-symptom onset on the left graph. On the right graph, data for first and second samplings were pooled. *p<0.05, **p<0.01, ns. not significant (Wilcoxon test). See also Table S4 .

Further information and requests for resources and reagents should be directed to the Lead Contact Timothée Bruel (timothee.bruel@pasteur.fr).

This study did not generate new unique reagents.

This study did not generate or analyze datasets or code. Video S1 is available from Mendely data at http://dx/doi/org/10.17632/xpmby6vgxz.1

Pre-pandemic sera were sampled from 200 anonymized healthy blood donors recruited between September 2014 and April 2019 at the Val d'Oise sites of EFS (the French blood agency). The ICAReB platform (BRIF code n°BB-0033-00062) of Institut Pasteur collects and manages bioresources following ISO (International Organization for Standardization) 9001 and NF S 96-900 quality standards. More information about the participants included can be found in Table S1 .

Following the first documented local transmission of SARS-CoV-2 in France, outbreak investigation and contact tracing identified two cases in the high school of Crépy-en-Valois (France) on 2 February 2020. We conducted two retrospective seroepidemiological studies in the city:

(i) First, a retrospective closed cohort study in the high school 42 . Between 30 March and 4 April, all pupils, as well as teachers and non-teaching staff (administrative, cleaners, catering) from the high school were invited to participate in the investigation (n=1200). Participants completed a questionnaire which covered sociodemographic information and a 5 mL blood sample was taken (n=661). Some of the participants (n=203) had a previous blood sampling as part of an initial investigation of the cluster on March 3-4, 2020. More information about the participants included can be found in Table S2. (ii) Second, an investigation across primary schools 43 . We invited all pupils, teachers and nonteaching staff (administrative, cleaners, catering) from each of the six primary schools who were registered at the school from the beginning of the epidemic (estimated around 13 January 2020) up to the time of the investigation on April 28-30, 2020. Participants (with the help of their parents in the case of pupils) completed a questionnaire that covered sociodemographic information and a 5 mL blood sample was taken (n=1340). More information about the participants included can be found in Table S3 . These studies are registered with Clinicaltrials.gov (ID: NCT04325646) and received ethical approval by the Comité de Protection des Personnes Ile-de-France (CPP-IDF) III. Informed consent was obtained from all study participants. The ICAReB platform (BRIF code n°BB-0033-00062) of Institut Pasteur collected and managed bioresources following ISO (International Organization for Standardization) 9001 and NF S 96-900 quality standards.

Serum samples from hospitalized COVID-19 cases were obtained from Hôpital Bichat-Claude-Bernard as part of the French COVID-19 cohort. Each participant provided written consent to participate in the study, which was approved by the regional investigational review board (CPP-IDF VII, Paris, France) (ID RCB: 2020-A00256-33) and performed according to European guidelines and the Declaration of Helsinki. More information about the participants included can be found in Table S4 .

Raji cells (ATCC® CCL-86™) were grown in complete RPMI medium (10% Fetal Calf Serum (FCS), 1% Penicillin/Streptomycin (PS)). 293T cells (ATCC® CRL-3216™) and U2OS cells (ATCC® HTB-96™) were grown in complete DMEM medium (10% FCS, 1% PS). A549 cells (ATCC® CCL-185™) were cultured in F-12K Nutrient Mixture Media with 10% FCS and 1% PS. 293T, U2OS and A549 cells stably expressing ACE2, and U2OS-ACE2 cells stably expressing the GFPsplit system (GFP1-10 and GFP11; S-Fuse cells) were previously described 29 . Blasticidin (10 µg/mL) and puromycin (1 µg/mL) were used to select for ACE2 and GFPsplit transgenes expression, respectively. 293T and Raji cells stably expressing the SARS-CoV-2 Spike protein (GenBank: QHD43416.1) were generated by lentiviral transduction and selection with puromycin (1 µg/mL). Absence of mycoplasma contamination was confirmed in all cell lines with the Mycoalert™ Mycoplasma Detection Kit (Lonza). All cell lines were cultured at 37°C and 5% CO 2 .

Peripheral blood mononuclear cells (PBMCs) were isolated from peripheral blood of healthy human donors from the Etablissement Français du Sang (EFS), in accordance with local ethical guidelines. NK cells were enriched by magnetic negative selection (Miltenyi) and cultured overnight (37°C) in complete RPMI medium before use. More information about the participants included can be found in Table S1 .

The SARS-CoV-2 strain BetaCoV/France/IDF0372/2020 was supplied by the National Reference Centre for Respiratory Viruses hosted by Institut Pasteur (Paris, France). The human sample from which the strain was isolated has been provided by Dr. X. Lescure and Pr. Y. Yazdanpanah from the Bichât Hospital, Paris, France. The viral strain was supplied through the European Virus Archive goes Global (Evag) platform (Horizon 2020 research and innovation grant n°653316). Titration of viral stocks was performed on Vero E6, with a limiting dilution technique allowing a calculation of PFU (plaque-forming unit)/ml.

The S-Flow assay was performed as previously described 19 . Briefly, 293T-S were incubated at 4°C for 30 min with sera (1:300 dilution, unless otherwise specified) in PBS containing 0.5% BSA and 2 mM EDTA, washed with PBS, and stained using either anti-IgG Alexa Fluor 647 (dilution 1:600; Thermo Fisher Scientific), or anti-IgM Alexa Fluor 488 (dilution 1:600; Thermo Fisher Scientific), or anti-IgA Alexa Fluor 647 (dilution 1:800; Jackson ImmunoResearch). Cells were washed with PBS and fixed for 10 min using 4% paraformaldehyde (PFA). Data were acquired on an Attune NxT instrument (Life Technologies). Specific binding was calculated with the following formula: 100 × (% binding on 293T-Spike − % binding on control cells)/(100 − % binding on control cells).

A multiplex Luminex® MAGPIX® assay was developed to measure IgG antibody responses to SARS-CoV-2 antigens (trimeric Spike, S1, S2 RBD, Nucleoprotein), Nucleoprotein from two seasonal coronaviruses (NL63 and 229E), and antigens from other viruses (Influenza A H1N1, adenovirus type 40, mumps, rubella) 63 .

ADCC assay on infected cells 4x10 3 U2OS-ACE2-GFP-1-10 and 4x10 3 U2OS-ACE2-GFP-11 cells were plated in a µClear 96-well plate (Greiner Bio-One). The next day, cells were infected at a multiplicity of infection (MOI) of 0.1 for 18h. NK cells isolated from PBMCs of a healthy donor (ratio 1:1 unless otherwise stated) and sera from pre-pandemic or COVID-19 individuals (dilution 1:100 unless otherwise stated) were added. After 4 hours, cells were fixed with 2% PFA, washed, stained with Hoechst (dilution 1:1,000, Invitrogen) and acquired with an Opera Phenix high content confocal microscope (PerkinElmer). The GFP area was quantified with the Harmony software (PerkinElmer). ADCC was measured using the following formula: 100 x (GFP area in "no serum" -GFP area in "tested serum")/(GFP area in "no serum").

ADCC was quantified using the ADCC Reporter Bioassay (Promega) according to manufacturer's instructions. Briefly, 5x10 4 Raji-Spike cells were co-cultured with 5x10 4 Jurkat-CD16-NFAT-rLuc cells in presence or absence of pre-pandemic or COVID-19 sera at the indicated dilution. Luciferase was measured after 18 hours of incubation using an EnSpire plate reader (PerkinElmer). ADCC was measured as the fold induction of Luciferase activity compared to the "no serum" condition.

Complement activation assay on infected cells 1.5x10 4 A549-ACE2 cells were plated in 96-well plates. After overnight incubation, cells were infected at a MOI of 1 for 24 hours. Then, pre-pandemic or COVID-19 serum was added as a source of antibodies (dilution 1:100) and normal (NHS) or heat-inactivated (HIHS) serum was added as a source of complement (dilution 1:2). After 4 hours, cells were detached using PBS-EDTA and incubated 30 min at 4°C with an APC-conjugated anti-C3b/iC3b antibody (clone 6C9, Tebu-bio, dilution 1:50). Cells were washed with PBS and fixed with 4% PFA. For Spike staining, cells were incubated 30 min with a biotinylated anti-Spike monoclonal antibody (10 µg/mL in PBS/BSA 0.5%/Saponin 0.05%), washed, and incubated 30 min with Streptavidin R-PE (dilution 1:100 in PBS/BSA 0.5%/Saponin 0.05%, Invitrogen). The anti-Spike antibody was a kind gift of Hugo Mouquet (Institut Pasteur, Paris). Data were acquired on an Attune NxT instrument (Life Technologies). For each serum, complementdependent cytotoxicity (CDC) of infected cells was calculated using the following formula: 100 × (% of infected cells with HIHS − % of infected cells with NHS)/(% of infected cells with HIHS).

Complement-dependent cytotoxicity (CDC) of Raji cells was measured as previously described 30 . Briefly Raji-Spike cells (5x10 4 ) were cultivated in the presence of 50% normal (NHS) or heatinactivated (HIHS) human serum and with or without pre-pandemic or COVID-19 sera (diluted 1:33 unless otherwise stated). After 24h, cells were washed with PBS and the live/dead fixable aqua dead cell marker (1:1,000 in PBS; Life Technologies) was added for 30 min at 4°C before fixation. Data were acquired on an Attune NxT instrument (Life Technologies). CDC was calculated using the following formula: 100 × (% of dead cells with serum − % of dead cells without serum)/(100 − % of dead cells without serum).

Pseudo-neutralization assay 2x10 4 293T-ACE2 cells were plated in 96-well plates. Single cycle lentiviral Spike pseudotypes encoding for a luciferase reporter gene were preincubated 30 minutes at room temperature with the serum to be tested at the indicated dilution and added to the cells. The luciferase signal was measured after 48h. The percentage of neutralization was calculated with the following formula, setting the "no serum" condition at 0% and the "no-pseudotype" condition at 100%: 100 x (1 -(value with serum -value with "no-pseudotype")/(value with "no serum" -value with "no-pseudotype")).

3 U2OS-ACE2-GFP-1-10 and 4x10 3 U2OS-ACE2-GFP-11 cells were plated overnight in a µClear 96-well plate (Greiner Bio-One). SARS-CoV-2 was incubated with sera at the indicated dilutions for 30 minutes at room temperature and added on cells (MOI 0.1). 18 hours later, cells were fixed with 2% PFA, washed, stained with Hoechst (dilution 1:1,000, Invitrogen) and acquired with an Opera Phenix high content confocal microscope (PerkinElmer). For each well, the GFP area and the number of nuclei were quantified using the Harmony software (PerkinElmer). The percentage of neutralization was calculated using the nuclei count or the GFP area using the following formula, setting the "no serum" condition at 0% and the non-infected condition at 100%: 100 x (1 -(value with serum -value in "non-infected")/(value in "no serum" -value in "non-infected")).

1x10 4 U2OS-ACE2-GFP-1-10 and 1x10 4 U2OS-ACE2-GFP-11 cells were plated overnight in each compartment of a µ-Dish35 mm Quad (Ibidi). The next day, cells were infected at a MOI of 0.1. 18 hours later, NK cells were added at 1:1 ratio as well as serum from a pre-pandemic or a COVID-19 individual (dilution 1:100). Conditions without NK and Serum ("No serum No NK") and with NK cells but without serum ("no serum") were included as controls. Propidium iodide (PI) (10 µg/ml, Invitrogen) was added to monitor cell death. Transmission and fluorescence images were acquired at a 20X magnification every 4 minutes for 4 hours on a BioStation IM-Q (Nikon). At least 5 fields were recorded in each condition. Images were analyzed using the FIJI software. Supplementary Movie S1 (related to Figure 2 ) Time-lapse of the ADCC of an infected cell by a NK cell in the presence of a COVID-19 serum. The syncytia appear in green (GFP). PI was added to monitor cell death and appears in red. The NK cell that comes and contacts the infected cell is indicated with a white arrowhead. Time post addition of NK cells and serum is indicated. Scale bar: 30µm.

-Asymptomatic and symptomatic individuals harbor polyfunctional antibodies. Days after symptom onset Complement ED50 1 2 Sampling ns.

IgG ADCC 

A new coronavirus associated with human respiratory disease in China

A pneumonia outbreak associated with a new coronavirus of probable bat origin

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

Estimating the effects of nonpharmaceutical interventions on COVID-19 in Europe

Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Natural History of Asymptomatic SARS-CoV-2 Infection

Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo'

Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

Longitudinal analyses reveal immunological misfiring in severe COVID-19

Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure

Heightened innate immune responses in the respiratory tract of COVID-19 patients

Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis

Endothelial cell infection and endotheliitis in COVID-19

A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations

Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Broad neutralization of SARS-related viruses by human monoclonal antibodies

Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Syncytia formation by SARS-CoV-2 infected cells

Anti-HIV -1 antibodies trigger non-lytic complement deposition on infected cells

Elimination of HIV-1-infected cells by broadly neutralizing antibodies

Comparison of Antibody-Dependent Cell-Mediated Cytotoxicity and Virus Neutralization by HIV-1 Env-Specific Monoclonal Antibodies

Impact of HIV-1 Envelope Conformation on ADCC Responses

The Fc Domain of Immunoglobulin Is Sufficient to Bridge NK Cells with Virally Infected Cells

Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity

Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection

A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus

Beyond binding: antibody effector functions in infectious diseases

Distinct early serological signatures track with SARS-CoV-2 survival

Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity

Cluster of COVID-19 in northern France: A retrospective closed cohort study. medRxiv

SARS-CoV-2 infection in primary schools in northern France: A retrospective cohort study in an area of high transmission

Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19

Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients

COVID-19-neutralizing antibodies predict disease severity and survival

SARS-CoV-2 Infection Severity Is Linked to Superior Humoral Immunity against the Spike

Complement as a target in COVID-19?

Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset

Cross-sectional evaluation of humoral responses against SARS-CoV-2 Spike

SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract

Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study

Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures

Construction of a human cell landscape at single-cell level

IgA dominates the early neutralizing antibody response to SARS-CoV-2

Different Innate and Adaptive Immune Responses to SARS-CoV-2 Infection of Asymptomatic, Mild, and Severe Cases

SARS-CoV-2 vaccines in development

Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection in vivo

Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection

Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection

Multiplex assays for the identification of serological signatures of SARS-CoV-2 infection: an antibody-based diagnostic and machine learning study

We thank the individuals who donated their blood. We thank M.M. Rajah for critical reading of the manuscript; J. Toubiana and S. Brisse (Institut Pasteur) for providing pre-pandemic serum samples; R. Lemahieu for organizing the epidemiological survey; and the ICAReB team for management and distribution of serum samples. We thank F. Mentre, S. Tubiana, the French COVID-19 cohort, and REACTing for cohort management. We thank S. Ferandes Pellerin and N. Jolly for their coordination